Avutometinib and Defactinib

Brand names: Avmapki Fakzynja Co-Pack · Active ingredient: Avutometinib Potassium, Defactinib Hydrochloride

In short: AVMAPKI FAKZYNJA CO-PACK is indicated for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. This indication is approved under accelerated approval based on tumor response rate and duration of response .

Forms & strengthsAVMAPKI FAKZYNJA CO-PACK is AVMAPKI (avutometinib) capsules co-packaged with FAKZYNJA (defactinib) tablets. AVMAPKI capsules contain 0.8 mg avutometinib and are white capsules with "6766" printed on the cap and the strength "0.8 mg" printed on the body in …
LabelVerastem Inc.
Label updatedMay 23, 2025

What is Avutometinib and Defactinib used for?

AVMAPKI FAKZYNJA CO-PACK is indicated for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.

This indication is approved under accelerated approval based on tumor response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Avutometinib and Defactinib dosage

Select patients for the treatment of recurrent LGSOC with AVMAPKI FAKZYNJA CO-PACK based on the presence of a KRAS mutation in tumor specimens .

An FDA-approved test for the detection of a KRAS mutation in LGSOC for selecting patients for treatment with AVMAPKI FAKZYNJA CO-PACK is not available.

Ophthalmic Exams

Conduct a comprehensive ophthalmic exam at baseline, prior to cycle 2, and every three cycles thereafter regardless of baseline exam findings, and as clinically indicated .

Prophylactic Medications for Skin Reactions

With initiation of and during at least the first 2 cycles of AVMAPKI FAKZYNJA CO-PACK administer :

Topical corticosteroid (applied to the face, scalp, neck, upper chest and upper back)

Systemic oral antibiotics

AVMAPKI Capsules

The recommended dosage of AVMAPKI capsules is 3.2 mg (four 0.8 mg capsules) taken orally twice weekly (Day 1 and Day 4) for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity.

Take AVMAPKI at the same time with each dose. AVMAPKI should be taken with food . Swallow capsules whole. Do not chew, break, or open the capsules.

If a dose of AVMAPKI is missed by more than 24 hours, skip the missed dose and take the next scheduled dose as prescribed. Do not take two doses at the same time to make up for a missed dose. If vomiting occurs after taking AVMAPKI, do not take an additional dose. Take the next scheduled dose as prescribed.

FAKZYNJA Tablets

The recommended dosage of FAKZYNJA tablets is 200 mg (one tablet) taken orally twice daily for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity.

Take each dose of FAKZYNJA with food . Swallow tablets whole. Do not chew, break or crush the tablets.

If a dose of FAKZYNJA is missed by more than 6 hours, skip the missed dose and take the next scheduled dose as prescribed. Do not take two tablets at the same time to make up for a missed dose. If vomiting occurs after taking FAKZYNJA, do not take an additional dose. Take the next scheduled dose as prescribed.

Dose reductions due to adverse reactions due to AVMAPKI FAKZYNJA CO-PACK are summarized in Table 1.

Dose Level | AVMAPKI Capsule | FAKZYNJA Tablet

Starting dose | 3.2 mg twice weekly for first 3 weeks of each 4-week cycle | 200 mg twice daily for first 3 weeks of each 4-week cycle

Dose reduction | 2.4 mg twice weekly for first 3 weeks of each 4-week cycle | 200 mg once daily for first 3 weeks of each 4-week cycle

Permanently discontinue both AVMAPKI and FAKZYNJA in patients unable to tolerate after one dose reduction of both products.

Dosage modifications for adverse reactions to AVMAPKI FAKZYNJA CO-PACK are summarized in Table 2. …

How to take Avutometinib and Defactinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Ocular Toxicities

Inform patients of the need for eye exams before and during treatment with AVMAPKI FAKZYNJA CO-PACK.

Advise patients to contact their healthcare provider if they experience any visual changes, pain, or inflammation around their eye(s) .

Serious Skin Toxicities

Inform patients that skin reactions have occurred during treatment with AVMAPKI FAKZYNJA CO-PACK.

Advise patients to use prophylactic topical steroids and oral antibiotics and to limit unnecessary exposure to sunlight with application of daily sunscreen (sun protection factor [SPF] ≥ 30) .

Advise patients to contact their healthcare provider if they develop a rash, progressively worsening skin reactions, or blistering of the skin or mouth .

Hepatotoxicity

Advise patients that they will need to undergo laboratory testing to monitor their liver function.

Advise patients to contact their healthcare provider for signs or symptoms of liver dysfunction .

Rhabdomyolysis

Inform patients that they will need to undergo laboratory testing to monitor CPK levels. …

Warnings & precautions

Do not take this medicine if: None.

AVMAPKI FAKZYNJA CO-PACK can cause ocular adverse reactions, including visual impairment and vitreoretinal disorders.

Ocular adverse reactions occurred in 68% of patients with recurrent LGSOC treated with AVMAPKI FAKZYNJA CO-PACK. Common ocular adverse reactions (≥ 5%) were visual impairment (38%), dry eye (13%), orbital/periorbital edema (8%), and vitreous floaters (5%). Thirty-five patients (26%) experienced vitreoretinal disorders, including retinal detachment (9%), and retinal vein occlusion (0.7%). Eighteen patients (13%) experienced an ocular adverse reaction that resulted in dose interruption of AVMAPKI FAKZYNJA CO-PACK and one patient experienced an ocular adverse reaction that resulted in dose reduction.

The median time to onset of symptomatic ocular adverse reactions was 5 days (range 1 to 943 days) and to onset of asymptomatic ocular adverse reactions was 112 days (range 23 to 943 days). The median time to onset of retinal detachment was 27 days (range 2 to 535 days). Of the patients who experienced ocular adverse reactions, 29% had ongoing ocular events at last follow-up.

Refer patients to a qualified eye care professional for a comprehensive ophthalmic exam at baseline, prior to cycle 2, every three cycles thereafter, and as clinically indicated. Promptly refer patients to an eye care professional for any new or worsening ocular signs or symptoms.

Monitor for ocular adverse reactions and withhold, reduce, or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and persistence of ocular adverse reactions .

AVMAPKI FAKZYNJA CO-PACK can cause serious skin toxicities, including Severe Cutaneous Adverse Reactions (SCARs). …

Avutometinib and Defactinib side effects

The following adverse reactions are discussed in more detail in other sections of the labeling:

Ocular Toxicities

Serious Skin Toxicities

Hepatotoxicity

Rhabdomyolysis

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety population described in Warnings and Precautions reflect exposure to the AVMAPKI FAKZYNJA CO-PACK (combination of AVMAPKI 3.2 mg twice weekly and FAKZYNJA 200 mg twice daily) for the first 3 weeks in a 4-week cycle until disease progression or unacceptable toxicity in 136 adult patients with recurrent LGSOC treated on RAMP-201 and FRAME (NCT03875820). The median duration of treatment was 10 months (range 0 to 51 months).

RAMP-201

The safety of AVMAPKI FAKZYNJA CO-PACK was evaluated in RAMP-201, a single-arm multicenter trial in 57 patients with KRAS-mutated recurrent LGSOC . Patients received AVMAPKI FAKZYNJA CO-PACK (AVMAPKI 3.2 mg twice weekly and FAKZYNJA 200 mg twice daily) for the first 3 weeks in a 4-week cycle until disease progression or unacceptable toxicity. The median duration of treatment was 12 months (range 0.03-40).

Serious adverse reactions occurred in 32% of patients who received AVMAPKI FAKZYNJA CO-PACK. …

Drug interactions

Strong and Moderate CYP3A4 Inhibitors

Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with strong or moderate CYP3A4 inhibitors.

Defactinib is a CYP3A4 substrate. Concomitant use of defactinib with a strong CYP3A4 inhibitor increases defactinib exposure , which may increase the risk of AVMAPKI FAKZYNJA CO-PACK adverse reactions.

Strong and Moderate CYP3A4 Inducers

Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with strong or moderate CYP3A4 inducers.

Defactinib is a CYP3A4 substrate. Concomitant use of defactinib with a strong CYP3A4 inducer decreases defactinib exposure, which may reduce the effectiveness of FAKZYNJA .

Gastric Acid Reducing Agents

Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with proton pump inhibitors (PPIs) or H2 receptor antagonists. If concomitant use of an acid-reducing agent cannot be avoided, administer FAKZYNJA 2 hours before or 2 hours after the administration of a locally acting antacid.

Concomitant use of FAKZYNJA with gastric acid reducing agents decreases defactinib exposure, which may reduce the effectiveness of AVMAPKI FAKZYNJA CO-PACK .

Warfarin

Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with warfarin. For patients requiring anticoagulation, an alternative to warfarin is recommended. …

About this medicine

AVMAPKI FAKZYNJA CO-PACK contains AVMAPKI (avutometinib) capsules co-packaged with FAKZYNJA (defactinib) tablets.

AVMAPKI capsules contain avutometinib, a kinase inhibitor. The chemical name of avutometinib is N-(3-Fluoro-4-{[4-methyl-7-(2-pyrimidinyloxy)-2H-chromen-2-on-3-yl]methyl}-2-pyridyl)-N'-methylsulfamide potassium salt. The molecular formula for avutometinib is C21H17FN5O5S (as potassium salt) and its molecular weight is 509.55. The chemical structure of avutometinib is shown below:

Avutometinib potassium is a white to pale yellow powder. It is practically insoluble in the pH range of 1 to 7 in aqueous media. The pKa is 7.02. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 65889527-1406-45df-8a85-e2690dcf427d. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate